August 31, 2021 SARC024 Texas Children’s Cancer and Hematology Centers is now open to enrollment in SARC024 (Regorafenib/Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas). SARC024 sites include: • Atrium Health Levine Cancer Institute (Atlanta, GA)• … Read more
May 24, 2021 Understanding Adoptive Cell Therapy for Sarcoma Adoptive Cell Therapy is a type of cancer treatment that uses your own immune system to treat your cancer; it may be an option for patients with some types of … Read more
March 9, 2021 A message from SARC Medical Officer Scott Okuno: Open Clinical Trials Message (excerpt) from Dr. Okuno to SARC Members: SARC has several “open, active, enrolling clinical trials [including] extremity soft tissue sarcoma trial using radiation therapy and immunotherapy neoadjuvantly…for advanced metastatic … Read more
January 15, 2021 New Study in Ewing Sarcoma Open to Enrollment SARC037 is a phase I study protocol to determine the recommended dose of trabectedin given as a 1-hour infusion in combination with low dose irinotecan. All patients enrolled will receive trabectedin combination … Read more
December 1, 2020 Launch of Phase 2 Clinical Trial for Patients with Clear Cell Sarcoma of Soft Tissue SARC is proud to partner with Sara’s Cure and Rafael Pharmaceuticals for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear … Read more
November 30, 2020 Open Accruing SARC Studies Open accruing studies for you to refer or enroll your patients: SARC024 for Rhabdomyosarcoma (alveolar and embryonal) and Mesenchymal Chondrosarcoma SARC031 for Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve … Read more
January 18, 2019 LILLY REPORTS RESULTS OF PHASE 3 SOFT TISSUE SARCOMA Today, Eli Lilly reported that the results of their Phase 3 study of olaratumab (LARTRUVO®) in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue … Read more
June 28, 2018 SARC Investigator-Initiated Osteosarcoma Study Shows Positive Results of Regorafenib SARC (Sarcoma Alliance for Research Through Collaboration) is pleased to report the positive results of their osteosarcoma trial of regorafenib. The goal of improving progression-free survival for patients receiving regorafenib … Read more
May 10, 2018 SARC009 PUBLISHED JAMA Oncology Publication of SARC Study of Dasatinib Under the leadership of Dr. Scott Schuetze, Professor at the Rogel Cancer Center, Michigan Medicine, the results of the collaborative trial of … Read more
June 22, 2017 SARC-SUPPORTED RESEARCH SHOWS PEMBROLIZUMAB A POTENTIALLY VIABLE TREATMENT FOR A SUBSET OF SARCOMAS SARC (Sarcoma Alliance for Research Through Collaboration) is pleased to report promising clinical trial results presented recently at ASCO 2017, the Annual Meeting of sarcoma cancer researchers. Melissa A. Burgess, … Read more